Genetic variation in adducin, a protein associated with the inner leaflet of the plasma membrane, may be in part responsible for salt-sensitive hypertension. In the Netherlands, 560 men who survived a myocardial infarction and 646 men who had undergone an orthopaedic intervention participated in a case-control study. In men in this study, the ␣-adducin polymorphism was not associated with the risk of myocardial infarction either among those with or among those without a clinical his-
Introduction
Genetic variation in adducin, a protein associated with the inner leaflet of the plasma membrane, may be in part responsible for salt-sensitive hypertension. 1 The Gly460 → Trp polymorphism of an ␣-adducin subunit is associated with hypertension in French and Italian populations. 2 Blood pressure responses to acute salt-sensitivity tests and to chronic diuretic therapy were more pronounced in heterozygotes than in wild-type homozygotes. 2 In a Japanese population, however, the ␣-adducin polymorphism was not associated with hypertension 3 even though the phenotype of salt-sensitivity has been associated with an increased risk of cardiovascular events among Japanese patients with essential hypertension. 4 Using data from a large Dutch case-control study of myocardial infarction, 5 we examined the associations of the ␣-adducin polymorphism with level of blood pressure and risk of myocardial infarction.
Subjects and methods
The methods have been described in detail. 5 Briefly, cases were men aged less than 70 years and hospitalised with first myocardial infarction in Leiden, The Netherlands, between January 1990 and January 1996. Controls were men who had received prophylactic anticoagulants briefly after an orthopaedic intervention between January 1990 and May 1996. The controls were frequency matched to the cases within 10-year age groups. Controls were excluded if they had had a previous myocardial infarction. Subjects (case and controls) were excluded if they had renal disease, severe neuropsychiatric problems, or a life expectancy of less than 1 year. Response rates among eligible subjects were 84.3% for cases and 77% for controls.
All subjects completed a risk-factor questionnaire concerning cardiovascular risk factors such as smoking, alcohol intake, medical history of hypertension, and the use of selected medications. Blood pressure was measured in a standardised fashion with the person seated after 10 min rest during the visit when the fasting blood sample was obtained. Using published information, 2 genetic analysis for the ␣-adducin polymorphism was performed with a polymerase chain reaction (PCR) using a mutagenic primer that introduced a BstXI site in the product of the Trp-containing allele. The PCR-product of both alleles contained an additional invariant BstXI-site that was used as a positive control for the restriction enzyme digestion.
Statistical analysis involved the use of odds ratios, and analysis of variance was used for the blood pressure levels.
Results
During the study period, 560 men who survived a myocardial infarction and 646 men who had under-gone an orthopaedic intervention participated in this case-control study. The mean age of the case (56.2 years) did not differ from that of the controls (57.3 years). As expected, traditional risk factors such as smoking were associated with the risk of myocardial infarction in this population. 5 Selfreported hypertension was also associated with the risk of myocardial infarction (odds ratio (OR) = 1.84, 95% CI = 1.42-2.42).
Among 646 controls, 34.4% were heterozygous and 5.9% were homozygous for the Trp460, variant allele. In the analysis of the case-control data, subjects without hypertension and with the wild-type alleles for ␣-adducin served as the reference group ( Table 1 ). The ␣-adducin polymorphism was not associated with the risk of myocardial infarction either among those with or among those without hypertension. Among subjects without hypertension, the presence of one or two variant alleles had trivial effects on the risk of myocardial infarction (OR = 0.94 for both groups). For subjects with selfreported hypertension and the wild-type alleles for ␣-adducin, compared with non-hypertensives with the wild-type (the reference group), the risk of myocardial infarction was 1.59 (95% CI = 1.12-2.26). Among subjects with self-reported hypertension, the presence of one or two variant alleles increased the risk of myocardial infarction slightly from 1.59 for the wild-type to 2.17 for heterozygotes and 2.09 for homozygotes; but the differences between these odds ratios and 1.59 were not statistically significant. In the stratum of subjects with hypertension, the presence of either one or two variant alleles compared with the wild-type was only weakly associated with the risk of myocardial infarction (OR = 1.36; 95% CI = 0.83-2.24).
In a cross-sectional analysis of data from the controls, the ␣-adducin polymorphism was not associated with self-reported hypertension (OR = 0.78, 95% CI = 0.51-1.19). While self-reported hypertension was strongly associated with mean levels of systolic and diastolic blood pressure (P Ͻ 0.001; Table 1), the ␣-adducin polymorphism was not associated with levels of systolic or diastolic blood pressure (P Ͼ 0.1). Excluding subjects on antihypertensive drug treatment and adjusting for age and calendar year had trivial effects on the results. There was no interaction between diuretic drug treatment and genotype on blood pressure level. OR, odds ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure. For both SBP and DBP, the main effect of hypertension was statistically significant (P Ͻ 0.001), but the main effect of ␣-adducin and the interaction terms were not (P Ͼ 0.1 for all tests).
Discussion
In this study from the Netherlands, the prevalence of Trp460 variant allele of ␣-adducin was higher than in French and Italian populations (23.5% heterozygotes and 3.3% homozygotes among the controls 2 ). Previously associated with salt sensitivity, the adducin polymorphism was not associated with the risk of myocardial infarction in this study; and among controls, despite reasonable sample sizes, the adducin variant was not associated with either self-reported hypertension or with level of blood pressure.
In French and Italian populations, the Trp460 allele has been associated with both the occurrence of hypertension and the response to diuretic therapy. 2 Several recent studies have suggested that the ␣-adducin polymorphism affects renal sodium handling in hypertension. 6, 7 Despite these persuasive physiologic links, several other studies, like this one, have failed to find an association between the variant allele of ␣-adducin and hypertension in Anglo-Australians 8 and in Japanese patients.
3,9,10
The ␣-adducin polymorphism may be in linkage disequilibrium with other mutations that are responsible for salt sensitivity or the risk of hypertension. Issues related to control selection, case-fatality rates, and the possibility of unmeasured or unknown confounding factors remain potential alternative explanations for findings, including null findings, from case-control studies.
The ␣-adducin polymorphism is common; and if it affects either the incidence of hypertension or the response to diuretic therapy, this information would be important from the point of view of public health. Additional studies in other populations are needed to assess the contribution of the ␣-adducin polymorphism to high blood pressure and cardiovascular risk.
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